[
  {
    "ts": null,
    "headline": "Why Moderna Might Be a One-Hit Wonder",
    "summary": "Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.",
    "url": "https://finnhub.io/api/news?id=11c7e5e8d658510600469ad8d44203508d4b26e03400f3192955b46ffb4c3158",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760558925,
      "headline": "Why Moderna Might Be a One-Hit Wonder",
      "id": 137102017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.",
      "url": "https://finnhub.io/api/news?id=11c7e5e8d658510600469ad8d44203508d4b26e03400f3192955b46ffb4c3158"
    }
  },
  {
    "ts": null,
    "headline": "Merck: A Golden Buying Opportunity",
    "summary": "Merck's strong drug pipeline, oncology leadership, and 3.8% dividend yield make it a top long-term investment pick. Learn more about MRK stock here.",
    "url": "https://finnhub.io/api/news?id=d12ee016efeb7b58c12f7d6d21079609725ba2916e9d1a8623f1954cccd993c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760542981,
      "headline": "Merck: A Golden Buying Opportunity",
      "id": 137096757,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366567764/image_1366567764.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck's strong drug pipeline, oncology leadership, and 3.8% dividend yield make it a top long-term investment pick. Learn more about MRK stock here.",
      "url": "https://finnhub.io/api/news?id=d12ee016efeb7b58c12f7d6d21079609725ba2916e9d1a8623f1954cccd993c0"
    }
  },
  {
    "ts": null,
    "headline": "Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations",
    "summary": "Opportunities in the NSCLC market include the adoption of targeted and immunotherapies such as PD-1/PD-L1 inhibitors, the potential in Asia Pacific driven by rising prevalence, and advancements in personalized treatments through biomarker-driven therapy. Growth is also supported by increasing R&D and healthcare investment.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Non-Small Cell Lung Cancer Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competi",
    "url": "https://finnhub.io/api/news?id=d50bcbd6ac249c8ebcb4b6411344c21508850feb5b38fbad9309faf5868390c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760528640,
      "headline": "Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations",
      "id": 137094090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Opportunities in the NSCLC market include the adoption of targeted and immunotherapies such as PD-1/PD-L1 inhibitors, the potential in Asia Pacific driven by rising prevalence, and advancements in personalized treatments through biomarker-driven therapy. Growth is also supported by increasing R&D and healthcare investment.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Non-Small Cell Lung Cancer Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competi",
      "url": "https://finnhub.io/api/news?id=d50bcbd6ac249c8ebcb4b6411344c21508850feb5b38fbad9309faf5868390c1"
    }
  },
  {
    "ts": null,
    "headline": "Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships",
    "summary": "The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities include expanding vaccine access in developing countries, R&D in new vaccine technologies, and managing competition from generics.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Varicella Zoster Virus Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key",
    "url": "https://finnhub.io/api/news?id=70a4bb6a20498880e7c4939c6bd206a038bcce186a30948845ec8b4fbee82853",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760528040,
      "headline": "Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships",
      "id": 137094091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities include expanding vaccine access in developing countries, R&D in new vaccine technologies, and managing competition from generics.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Varicella Zoster Virus Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key",
      "url": "https://finnhub.io/api/news?id=70a4bb6a20498880e7c4939c6bd206a038bcce186a30948845ec8b4fbee82853"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection",
    "summary": "RAHWAY, N.J., October 15, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that was virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50 mg/200 mg/25 mg)] in trial MK-8591A-052 or antiretroviral therapy [baseline",
    "url": "https://finnhub.io/api/news?id=efb41ec0646278c8ef4ec893e5748993fac118bc3d21bf9c80c44138734a6c78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760525100,
      "headline": "Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection",
      "id": 137094092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 15, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that was virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50 mg/200 mg/25 mg)] in trial MK-8591A-052 or antiretroviral therapy [baseline",
      "url": "https://finnhub.io/api/news?id=efb41ec0646278c8ef4ec893e5748993fac118bc3d21bf9c80c44138734a6c78"
    }
  }
]